Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 10,125 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 10,125 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $26.07, for a total value of $263,958.75. Following the sale, the director owned 62,291 shares in the company, valued at approximately $1,623,926.37. The trade was a 13.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Wednesday, August 12th, Isaac Barchas sold 11,048 shares of Immunome stock. The stock was sold at an average price of $27.25, for a total value of $301,058.00.
• On Tuesday, August 11th, Isaac Barchas sold 62,291 shares of Immunome stock. The stock was sold at an average price of $26.23, for a total value of $1,633,892.93.
• On Friday, August 7th, Isaac Barchas sold 15,248 shares of Immunome stock. The shares were sold at an average price of $26.06, for a total value of $397,362.88.
• On Thursday, August 6th, Isaac Barchas sold 20,840 shares of Immunome stock. The stock was sold at an average price of $26.06, for a total transaction of $543,090.40.
• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20.
• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Stock Performance

Shares of IMNM opened at $27.99 on Thursday. The business’s 50-day moving average is $21.89 and its two-hundred day moving average is $22.20. The company has a market capitalization of $3.17 billion, a P/E ratio of -11.06 and a beta of 2.08. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $28.04.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). Analysts forecast that Immunome, Inc. will post -2.06 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunome in a report on Friday, July 17th. Leerink Partners decreased their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Finally, Truist Financial boosted their price target on Immunome from $37.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday. Twelve equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average price target of $34.64.

Hedge Funds Weigh In On Immunome

A number of institutional investors have recently bought and sold shares of IMNM. BlackRock Inc. purchased a new stake in shares of Immunome in the 2nd quarter valued at approximately $186,588,000. T. Rowe Price Investment Management Inc. raised its position in shares of Immunome by 59.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock valued at $288,305,000 after buying an additional 5,003,824 shares during the period. JPMorgan Chase & Co. lifted its holdings in Immunome by 8,659.2% in the fourth quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after acquiring an additional 2,823,144 shares during the last quarter. Primecap Management Co. CA lifted its holdings in Immunome by 55.2% in the fourth quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after acquiring an additional 1,667,432 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Immunome in the fourth quarter worth approximately $30,710,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

More Immunome News

Here are the key news stories impacting Immunome this week:

• Positive Sentiment: Truist’s higher price target and Buy rating likely supported investor enthusiasm and helped drive IMNM toward a fresh 52-week high. Truist price target update
• Positive Sentiment: Immunome reported second-quarter 2026 results and provided a business update. Investors continue to focus on the company’s clinical pipeline and progress in its antibody-based oncology and infectious-disease programs, which are central to its valuation. Immunome second-quarter 2026 results and business update
• Neutral Sentiment: Director Isaac Barchas sold 98,712 shares from August 10 through August 12 for approximately $2.6 million, reducing his direct ownership to 92,211 shares. The sales occurred under a pre-arranged Rule 10b5-1 plan, making them less conclusive as a signal of management’s current outlook. Immunome director insider sales SEC filing
• Negative Sentiment: Immunome reported a quarterly loss of $0.65 per share, wider than the consensus loss estimate of $0.51. The miss highlights continued cash-burn and execution risks for the clinical-stage biotechnology company. Immunome quarterly earnings release

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.